Kai Liang Teh1, Lena Das1, Yun Xin Book1, Sook Fun Hoh2, Xiaocong Gao2, Thaschawee Arkachaisri3,4. 1. Rheumatology and Immunology Service, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore. 2. Division of Nursing, KK Women's and Children's Hospital, Singapore, Singapore. 3. Rheumatology and Immunology Service, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore. thaschawee.arkachaisri@singhealth.com.sg. 4. Duke-NUS Medical School, Singapore, Singapore. thaschawee.arkachaisri@singhealth.com.sg.
Abstract
OBJECTIVES: To assess short- and long-term outcomes of ERA in a large monocentric cohort in Singapore. METHODS: Children diagnosed with ERA according to ILAR criteria from 2002 to 2021 were recruited. Nonparametric statistics were used to describe the data. Outcomes were defined according to modified Wallace criteria, and probabilities and predictors were determined using Kaplan-Meier survival and logistic regression analyses. RESULTS: One hundred fifty-one ERA patients (male 86%; Chinese 81%) were included. The median age at onset was 11.9 years (IQR: 9.4-13.9), and disease duration was 5.3 years (IQR: 2.9-8.4). At diagnosis, 39% of the patients had sacroiliitis. HLA-B27 was positive in 83%, and biologics were used in 72% of the patients. Clinical inactive disease (CID) was achieved in 92% of the patients, of which 27% achieved within 6 months. Sacroiliitis at diagnosis is an unfavorable predictor of early CID at 6 months. Medication was discontinued in one-third of the patients. Favorable predictor of medication withdrawal includes male gender, while unfavorable predictors include positive HLA-B27 and ANA. Two-thirds of the patients with CID had at least one disease flare. Sacroiliitis at diagnosis is a protective predictor of flare after stopping medication. CONCLUSION: Despite a high proportion of ERA patients achieving CID, only one-third could stop medication with high rates of disease flare. Unfavorable predictors include older age at onset, HLA-B27, and ANA positivity. While sacroiliitis at diagnosis is a negative predictor of CID at 6 months, it is associated with less disease flare after discontinuing medication.
OBJECTIVES: To assess short- and long-term outcomes of ERA in a large monocentric cohort in Singapore. METHODS: Children diagnosed with ERA according to ILAR criteria from 2002 to 2021 were recruited. Nonparametric statistics were used to describe the data. Outcomes were defined according to modified Wallace criteria, and probabilities and predictors were determined using Kaplan-Meier survival and logistic regression analyses. RESULTS: One hundred fifty-one ERA patients (male 86%; Chinese 81%) were included. The median age at onset was 11.9 years (IQR: 9.4-13.9), and disease duration was 5.3 years (IQR: 2.9-8.4). At diagnosis, 39% of the patients had sacroiliitis. HLA-B27 was positive in 83%, and biologics were used in 72% of the patients. Clinical inactive disease (CID) was achieved in 92% of the patients, of which 27% achieved within 6 months. Sacroiliitis at diagnosis is an unfavorable predictor of early CID at 6 months. Medication was discontinued in one-third of the patients. Favorable predictor of medication withdrawal includes male gender, while unfavorable predictors include positive HLA-B27 and ANA. Two-thirds of the patients with CID had at least one disease flare. Sacroiliitis at diagnosis is a protective predictor of flare after stopping medication. CONCLUSION: Despite a high proportion of ERA patients achieving CID, only one-third could stop medication with high rates of disease flare. Unfavorable predictors include older age at onset, HLA-B27, and ANA positivity. While sacroiliitis at diagnosis is a negative predictor of CID at 6 months, it is associated with less disease flare after discontinuing medication.
Authors: Lillemor Berntson; Ellen Nordal; Kristiina Aalto; Suvi Peltoniemi; Troels Herlin; Marek Zak; Susan Nielsen; Marite Rygg Journal: J Rheumatol Date: 2013-04-01 Impact factor: 4.666
Authors: Kiem Oen; Lori Tucker; Adam M Huber; Paivi Miettunen; Rosie Scuccimarri; Sarah Campillo; David A Cabral; Brian M Feldman; Shirley Tse; Gaëlle Chédeville; Lynn Spiegel; Rayfel Schneider; Bianca Lang; Janet Ellsworth; Suzanne Ramsey; Paul Dancey; Earl Silverman; Anne-Laure Chetaille; Bonnie Cameron; Nicole Johnson; Jean Dorval; Ross E Petty; Karen Watanabe Duffy; Gilles Boire; Elie Haddad; Kristin Houghton; Claire Saint-Cyr; Stuart E Turvey; Susanne Benseler; Mary Cheang; Rae S M Yeung; Ciarán M Duffy Journal: Arthritis Rheum Date: 2009-08-15
Authors: Robert G W Lambert; Pauline A C Bakker; Désirée van der Heijde; Ulrich Weber; Martin Rudwaleit; K G Hermann; Joachim Sieper; Xenofon Baraliakos; Alex Bennett; Jürgen Braun; Rubén Burgos-Vargas; Maxime Dougados; Susanne Juhl Pedersen; Anne Grethe Jurik; Walter P Maksymowych; Helena Marzo-Ortega; Mikkel Østergaard; Denis Poddubnyy; Monique Reijnierse; Filip van den Bosch; Irene van der Horst-Bruinsma; Robert Landewé Journal: Ann Rheum Dis Date: 2016-01-14 Impact factor: 19.103